Physician profile
Stanley V Thomas
NPI 1942526371
$3,551.35
in general payments reported to CMS, 2019-2025
30 companies · $1,023 in 2025
The $1,023 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $239 · 2021: $142 · 2022: $277 · 2023: $724 · 2024: $999 · 2025: $1,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,566 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,566.07 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $810.16 | 2022-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $603.89 | 2020-2025 | Fasenra, Airsupra, Tezspire |
| Harmony Biosciences LLC | $394.06 | 2023-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.67 | 2019-2025 | Ofev, Jascayd |
| Jazz Pharmaceuticals INC. | $185.40 | 2023-2025 | |
| Grifols USA, LLC | $167.16 | 2019-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $139.46 | 2019-2025 | Dupixent |
| Itamar Medical INC | $131.64 | 2023 | Watchpatone |
| Amgen INC. | $123.69 | 2023-2024 | Tezspire |
| Mylan Specialty L.P. | $98.19 | 2019-2024 | Yupelri |
| Insmed, INC. | $80.30 | 2024-2025 | Arikayce |
| Genzyme Corporation | $74.59 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $60.05 | 2019-2024 | Opsumit, Uptravi |
| United Therapeutics Corporation | $49.20 | 2021-2023 | |
| Glaxosmithkline, LLC. | $40.92 | 2020-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $40.10 | 2021-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $37.13 | 2024 | Lumryz |
| Merck Sharp & Dohme LLC | $35.50 | 2025 | Winrevair |
| Vantive US Healthcare LLC | $32.73 | 2025 | Renal - Acute |
| Circassia INC. | $29.58 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $24.14 | 2020 | |
| Electromed, INC. | $21.92 | 2023 | Smartvest |
| Alexion Pharmaceuticals, INC. | $19.39 | 2024 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $18.18 | 2023 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $17.63 | 2020 | |
| Viatris Specialty LLC | $16.41 | 2025 | Yupelri |
| Verona Pharma, INC. | $15.92 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $14.88 | 2025 | Mounjaro |
| Axsome Therapeutics, INC. | $14.22 | 2024 | Sunosi |
| Genentech USA, INC. | $13.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.